References

Biology and treatment of richter transformation

10.3389/fonc.2022.829983 · 2022 · External reference

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

10.1182/blood.2024028064 · 2025 · External reference

Molecular pathogenesis and targeted treatment of richter transformation

10.3390/biomedicines14020347 · 2026 · External reference

The journey of antibody–drug conjugates: lessons learned from 40 years of development

10.1158/2159-8290.cd-24-0708 · 2024 · External reference

Exploration of the antibody–drug conjugate clinical landscape

10.1080/19420862.2023.2229101 · 2023 · External reference

Antibody–drug conjugates in hematological malignancies: current landscape and future perspectives

10.3390/ijms27021025 · 2026 · External reference

ROR1 targeting with the antibody–drug conjugate VLS‐101 is effective in Richter syndrome patient‐derived xenograft mouse models

10.1182/blood.2020008404 · 2021 · External reference

Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers

2022 · External reference

Therapeutic advances in the targeting of ROR1 in hematological cancers

10.1038/s41420-024-02239-1 · 2024 · External reference

Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study

10.1002/hon.3164_427 · 2023 · External reference

Phase 2 study of zilovertamab vedotin in participants with metastatic solid tumors

10.1158/2767-9764.crc-25-0019 · 2025 · External reference

Analysis of ROR1 protein expression in human cancer and normal tissues

10.1158/1078-0432.ccr-16-2083 · 2017 · External reference

Unique cell surface expression of receptor tyrosine kinase ROR1 in human B‐cell chronic lymphocytic leukemia

10.1158/1078-0432.ccr-07-1823 · 2008 · External reference

ROR1 is expressed in diffuse large B‐cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells

10.3390/biomedicines8060170 · 2020 · External reference

High expression level of ROR1 and ROR1‐signaling associates with venetoclax resistance in chronic lymphocytic leukemia

10.1038/s41375-022-01543-y · 2022 · External reference

ROR1: an orphan becomes apparent

10.1182/blood.2021014760 · 2022 · External reference

Canonical and noncanonical Wnt signaling: multilayered mediators, signaling mechanisms and major signaling crosstalk

10.1016/j.gendis.2023.01.030 · 2024 · External reference

Evolutionary conservation and cancer implications of the WNT signaling pathway

10.1007/s12032-025-02950-8 · 2025 · External reference

Looking lively: emerging principles of pseudokinase signaling

10.1016/j.tibs.2022.04.011 · 2022 · External reference

WNT signaling in hematological malignancies

10.3389/fonc.2020.615190 · 2020 · External reference

The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction

10.1101/cshperspect.a009175 · 2014 · External reference

Targeting Wnt signaling pseudokinases in hematological cancers

10.1111/ejh.13137 · 2018 · External reference

Structural insights into pseudokinase domains of receptor tyrosine kinases

10.1016/j.molcel.2020.06.018 · 2020 · External reference

Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses

10.1158/0008-5472.can-17-4004 · 2018 · External reference

Anti‐CD37 α‐amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome

10.1182/blood.2022016211 · 2022 · External reference

The biochemistry, signalling and disease relevance of RYK and other WNT‐binding receptor tyrosine kinases

2018 · External reference

Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies

10.1038/s41375-026-02964-9 · 2026 · External reference

Exploring the next generation of antibody–drug conjugates

10.1038/s41571-023-00850-2 · 2024 · External reference

FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma

10.1158/1078-0432.ccr-22-0618 · 2022 · External reference

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

2001 · External reference

Loncastuximab tesirine in relapsed/refractory diffuse large B‐cell lymphoma: long‐term efficacy and safety from the phase II LOTIS‐2 study

10.3324/haematol.2023.283459 · 2024 · External reference

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large‐cell lymphoma

10.1158/1078-0432.ccr-12-1803 · 2012 · External reference

Polatuzumab vedotin: first global approval

10.1007/s40265-019-01175-0 · 2019 · External reference

Inotuzumab ozogamicin: first global approval

10.1007/s40265-017-0802-5 · 2017 · External reference

EMA review of belantamab mafodotin (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma

10.1002/onco.13592 · 2021 · External reference

Polatuzumab vedotin in relapsed or refractory diffuse large B‐cell lymphoma

10.1200/jco.19.00172 · 2020 · External reference

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B‐cell lymphoma: an open‐label, non‐randomised, phase 1b‐2 study

10.1016/s1470-2045(19)30091-9 · 2019 · External reference

Polatuzumab vedotin in previously untreated diffuse large B‐cell lymphoma

10.1056/nejmoa2115304 · 2022 · External reference

First‐line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B‐cell lymphoma: a multicentre retrospective analysis

10.1080/07853890.2025.2566871 · 2025 · External reference

Reducing hydrophobicity of homogeneous antibody–drug conjugates improves pharmacokinetics and therapeutic index

10.1038/nbt.3212 · 2015 · External reference

Linker design impacts antibody–drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency

10.3389/fphar.2021.687926 · 2021 · External reference